Algernon Pharmaceuticals Incis A Canadian Clinical Stage Drug Development And Repurposing Companyit Focuses On Addressing Unmet Medical Needs In Areas Such As Non Alcoholic Steatohepatitisliver Diseasechronic Kidney Diseaseand Strokethe Company Employs A Capital Efficient Business Model That Emphasizes Maximizing Shareholder Value Through Drug Repurposingwhich Involves Finding New Uses For Existing Drugs Algernon Is Actively Developing Treatments For Several Therapeutic Areasincluding Stroke And Traumatic Brain Injury Through Its Subsidiaryalgernon Neurosciencethe Company Also Conducts Ongoing Research In Chronic Kidney Disease And Has Previously Worked On Chronic Cough And Idiopathic Pulmonary Fibrosisalgernon Collaborates With Industry Partnerssuch As Seyltx Inc And Facilitates Phase Ii Clinical Trials In Australiaengaging With Patients And Medical Institutions
